Multicenter evaluation of patients with cutaneous malignant melanoma in Turkey: MELAS study

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 533-537

  Ozlem, Uysal Sonmez ^a   Tanriverdi, Ozgur ^b   Esbah, Onur ^c   Uyeturk, Ummugul ^d   Helvaci, Kaan ^c   Bal, Oznur ^c   Ulku, Yalcintas Arslan ^c   Budakoglu, Burcin ^c   Oksuzoglu, Berna ^c  

^a SAKARYA UNIVERSITY   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^c Dr Abdurrahman Yurtarslan Oncology Education and Research Hospital   (Turkey)

^d ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Cutaneous malignant melanoma; Prognostic factors; Survival; Turkey

Indexed keywords

EID: 84877136840     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.533     Document Type: Article

References (20)

1. Balch CM, Buzaid AC, Soong SJ, et al (2001). Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol, 19, 3635-48.
2. Barnhill RL, Fine JA, Roush GC, Berwick M (1996). Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 78, 427-32.
3. Chao C, Martin RC, Ross MI, et al (2004). Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol, 11, 259-64.
4. Chi Z, Li S, Sheng X, et al (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer, 11, 85-95.
5. Gimotty PA, Botbyl J, Soong SH, Guerry D (2005). A population-based validation of the American Joint Committee on Cancer melanoma staging systemç. J Clin Oncol, 23, 8065-75.
6. Hainsworth JD, Infante JR, Spigel DR, et al (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah cannon oncology research consortium. Cancer, 116, 4122-9.
7. Hauschild A, Agarwala SS, Trefzer U, et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 27, 2823-30.
8. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
9. Lasithiotakis K, Leiter U, Meier F, et al (2008). Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 112, 1795-804.
10. Lindholm C, Andersson R, Dufmats M, et al (2004). Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer, 101, 2067-78.
11. MacKie RM, Bray C, Vestey J, et al (2007). Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer, 96, 1772-7.
12. Markovic SN, Erickson LA, Rao RD, et al (2007). Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc, 82, 490-513.
13. Mervic L (2012). Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerologica, 21, 27-31.
14. O'Day S, Hodi FS, McDermott DF, et al (2010). A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol, 28, 4.
15. Reed KB, Brewer JD, Lohse CM, et al (2012). Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc, 87, 328-34.
16. Spatz A, Cook MG, Elder DE, et al (2003). Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer, 39, 1861-5.
17. Tas F, Kurul S, Camlica H, Topuz E (2006). Malignant melanoma in Turkey: a single institution's experience on 475 cases. Jpn J Clin Oncol, 36, 784-9.
18. Thompson JF, Soong SJ, Balch CM, et al (2011). Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol, 29, 2199-205.
19. Uehara S, Kamo R, Harada T, Ishii M (2009). Survival analysis of malignant melanoma in Japan-multivariate analysis of prognostic factors. Osaka City Med J, 55, 35-52.
20. Verma S, Quirt I, McCready D, et al (2006). Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer, 106, 1431-42.